These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 15742548)

  • 1. [Editorial: Interview with Father Hervé Gallais, Conception Hospital, Marseille].
    Med Mal Infect; 2004 Sep; 34 Spec No 1():1-2. PubMed ID: 15742548
    [No Abstract]   [Full Text] [Related]  

  • 2. [Enfuvirtide. Two injections per day for HIV].
    Taéron C
    Rev Infirm; 2004 Oct; (104):35-6. PubMed ID: 15581312
    [No Abstract]   [Full Text] [Related]  

  • 3. Anti-HIV agents. Access denied--keeping HIV out with entry inhibitors.
    TreatmentUpdate; 2006; 18(4):4. PubMed ID: 17205653
    [No Abstract]   [Full Text] [Related]  

  • 4. [Enfuvirtida (Fuzeon). Laboratory: Roche & Trimeris].
    Moreno Alvarez PJ
    Farm Hosp; 2003; 27(4):271-2. PubMed ID: 12966457
    [No Abstract]   [Full Text] [Related]  

  • 5. Misleading efficacy claims for Fuzeon.
    AIDS Patient Care STDS; 2005 Sep; 19(9):614. PubMed ID: 16247841
    [No Abstract]   [Full Text] [Related]  

  • 6. T-20 being called "miraculous".
    AIDS Patient Care STDS; 2002 Sep; 16(9):462. PubMed ID: 12412581
    [No Abstract]   [Full Text] [Related]  

  • 7. [New drug class blocks virus-cell fusion. HIV not admitted].
    MMW Fortschr Med; 2003 Sep; 145(35-36):53. PubMed ID: 14584215
    [No Abstract]   [Full Text] [Related]  

  • 8. Katy, bar the door! HIV entry inhibitors.
    Martinez LJ
    Res Initiat Treat Action; 2000 Jun; 6(2):6-12. PubMed ID: 11707878
    [No Abstract]   [Full Text] [Related]  

  • 9. Enfuvirtide doubles chances for suppression.
    AIDS Patient Care STDS; 2004 Sep; 18(9):550. PubMed ID: 15630779
    [No Abstract]   [Full Text] [Related]  

  • 10. Enfuvirtide beneficial in experienced patients.
    AIDS Patient Care STDS; 2004 Jan; 18(1):57. PubMed ID: 15080095
    [No Abstract]   [Full Text] [Related]  

  • 11. Fuzeon combination highly effective.
    AIDS Patient Care STDS; 2006 Dec; 20(12):888. PubMed ID: 17219619
    [No Abstract]   [Full Text] [Related]  

  • 12. [New treatments against AIDS: fusion inhibitors].
    Holzgrabe U
    Pharm Unserer Zeit; 2004; 33(1):6. PubMed ID: 14968706
    [No Abstract]   [Full Text] [Related]  

  • 13. T-1249 development suspended.
    Huff B
    GMHC Treat Issues; 2003 Dec; 17(12):6. PubMed ID: 15011643
    [No Abstract]   [Full Text] [Related]  

  • 14. Formal approval for Fuzeon.
    AIDS Patient Care STDS; 2004 Dec; 18(12):736. PubMed ID: 15659885
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical trials for enfuvirtide (Fuzeon, T-20).
    Crabb C
    AIDS; 2003 Nov; 17(17):N13-4. PubMed ID: 15065580
    [No Abstract]   [Full Text] [Related]  

  • 16. [Fusion inhibitors. One year therapy with T-20--initial evaluation].
    Goebel FD
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046
    [No Abstract]   [Full Text] [Related]  

  • 17. US FDA approves new class of HIV therapeutics.
    Robertson D
    Nat Biotechnol; 2003 May; 21(5):470-1. PubMed ID: 12721558
    [No Abstract]   [Full Text] [Related]  

  • 18. First-line use of enfuvirtide-containing HAART regimen with dramatic clinical and immunological improvement in three cases.
    Bourgarit A; Lascoux C; Palmer P; Tuleja E; Pintado C; Farge D; Sereni D
    AIDS; 2006 Feb; 20(3):471-3. PubMed ID: 16439888
    [No Abstract]   [Full Text] [Related]  

  • 19. Fusion inhibitor trials halted.
    AIDS Patient Care STDS; 2004 Mar; 18(3):182-3. PubMed ID: 15112641
    [No Abstract]   [Full Text] [Related]  

  • 20. ConFuzeon reigns.
    Huff B
    GMHC Treat Issues; 2003 Apr; 17(4):10. PubMed ID: 12751446
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.